Regorafenib D3
| Product Name | Regorafenib D3 |
|---|---|
| Alternate Names | Regorafenib Stable Isotopes, Stable Isotopes of Regorafenib |
| CAT No. | CS-O-10712 |
| CAS No. | 1255386-16-3 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 485.83 g/mol |
| Mol. For. | C₂₁H₁₂D₃ClF₃N₄O₃ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Regorafenib |
| Purity | 98.17 |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F |
| Canonical Smiles | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F |
| InchIKey | FNHKPVJBJVTLMP-FIBGUPNXSA-N |
| Inchl | InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)/i1D3 |
| IUPAC | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuteriomethyl)pyridine-2-carboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Regorafenib D3, also known as Stivarga, is a medication used to treat cancerous tumours in the colon and rectum. It is a kinase inhibitor, which means that it works by blocking certain enzymes that promote the growth and spread of cancer cells. Regorafenib D3 is the deuterium labelled analogue of Regorafenib, which is an FDA approved drug that is used to treat gastrointestinal stromal tumors and metastatic colorectal cancer.
The chemical structure of Regorafenib D3 consists of 21 carbon atoms, 15 hydrogen atoms, and 3 oxygen atoms. It also contains 3 deuterium atoms, which are heavier isotopes of hydrogen. The molecular formula of Regorafenib D3 is C20H20ClF3N6O4D3.
Regorafenib D3 is typically administered orally, in the form of tablets. The recommended dosage and duration of treatment may vary depending on the specific type and stage of cancer being treated, as well as the patient's overall health and medical history.
Like all medications, Regorafenib D3 may cause side effects. Some common side effects include fatigue, nausea, diarrhea, loss of appetite, and high blood pressure. It is important to speak with a healthcare provider about any potential risks and benefits of taking this medication.
Get an Instant Quote
Related Compounds
Regorafenib 13CD3 N-Oxide | N-Demethyl Regorafenib D3 N-Oxide | Regorafenib 13CD3 N-Glucuronide | Regorafenib M4 metabolite 13C6 | Regorafenib N-oxide D3 |